THE CLINICAL, REGULATORY & COMMERCIAL IMPLICATIONS OF RAPID APPROVAL 12 JULY 2016 ST. PANCRAS RENAISSANCE HOTEL LONDON
|
|
- Augustine Cannon
- 6 years ago
- Views:
Transcription
1 THE CLINICAL, REGULATORY & COMMERCIAL IMPLICATIONS OF RAPID APPROVAL 12 JULY 2016 ST. PANCRAS RENAISSANCE HOTEL LONDON 1
2 Placeholder for speaker photo PAREXEL to insert THOMAS SHOOK, M.D. Executive Vice President, Clinical Research Services and Senior Medical Officer PAREXEL International Welcome & Introduction 2
3 Placeholder for speaker photo PAREXEL to insert EDITH FRÉNOY Director of Market Access European Federation of Pharmaceutical Industries and Associations (EFPIA) The Opportunity Presented in Rapid Approvals: Getting Medicines to Patients Faster 3
4 ABOUT EFPIA The European Federation of Pharmaceutical Industries and Associations (EFPIA) represents the pharmaceutical industry operating in Europe. Through its direct membership of 33 national associations and 40 leading pharmaceutical companies, EFPIA is the voice on the EU scene of 1,900 companies committed to researching, developing and bringing to patients new medicines that will improve health and the quality of life around the world. 4
5 POINTS TO ADDRESS The opportunity The challenge Temporary fixes? The case for change A longer-term view Supportive action 5
6 BOSTON, MASSACHUSETTS THE OPPORTUNITY 6
7 MEDICINES ARE SOME OF THE MOST POWERFUL TOOLS IN TREATING AND CURING DISEASES 2006: First vaccine for the prevention of cervical cancer First Rx for chronic chest pain in 20 years First once-a-day HIV medicine 2012: First drug to target root cause of cystic fibrosis First drug to treat Cushing s disease 2004: First anti-angiogenic medicine for cancer New Rx for most common form of lung cancer 2008: A new type of treatment for Crohn s disease The first Rx for symptoms of Huntington s disease 2010: 2 new multiple sclerosis drugs First therapeutic cancer vaccine 2014: Oral treatments for HepC provide cure rates upwards of 90% 17 new drugs to treat patients with rare diseases 7,000 medicines in development around the world : First new kidney cancer Rx in over a decade 3 new therapies for diabetes 2007: New class of medicines to treat high blood pressure First treatment for fibromyalgia 2009: First treatment for peripheral T- cell lymphoma First new Rx for gout in 40 years 2011: First lupus drug in 50 years 2 new personalized medicines First Immuno-Oncology for metastatic melanoma 2013: 2 new personalized medicines to treat the most dangerous forms of skin cancer A new oral treatment for multiple sclerosis Note: Dates of innovation provided by the US Food and Drug Administration (FDA) Source: Health Advances analysis; PhRMA 2015 Biopharmaceuticals in Perspective 7
8 FOR CANCER PATIENTS, LIFE EXPECTANCY CONTINUES TO IMPROVE The use of innovative medicines has made major contribution to recent advances Increase of 1.74 From , an improvement in population weighted mean life expectancy at birth of 1.74 years was seen across 30 OECD countries % % Innovative medicines are estimated to have contributed to 73% of this improvement once other factors are taken into account (e.g., income, education, immunization, reduction in risk factors, health system access) Other Contribution of Innovative Medicines 2009 Source: Lichtenberg, F: Pharmaceutical innovation and longevity growth in 30 developing OECD and high-income countries, (2012) 8
9 MEDICINES ARE TRANSFORMING OUTCOMES FOR PATIENTS LIVING WITH CHRONIC DISEASE Cardiovascular Disease In Europe, biopharmaceutical companies are currently developing 172 medicines* to treat heart disease, stroke and other cardiovascular diseases. 1 New PCSK9 inhibitors have revolutionized therapy for high cholesterol. Between 2000 and 2012, the death rate from cardiovascular disease fell 37% in the EU5, 27% in Japan, and 5% in Mexico. 2 Diabetes Between 2000 and 2012, new therapies contributed to a 48% and 31% decline in the diabetes death rate in Korea and Canada, respectively. 2 Rheumatoid Arthritis The recent introduction of disease-modifying therapies has dramatically improved the lives of patients and caregivers by slowing and sometimes even reversing negative physical symptoms of the disease. 3 Death rates for noncommunicable diseases declined nearly 20% in the EU5, Australia, Canada, and Japan from 2000 to *Medicines in Phase I through III of development Note: The 4 main types of non-communicable diseases, also known as chronic diseases, defined by WHO are cardiovascular diseases (e.g., heart attacks and stroke), cancers, chronic respiratory diseases (e.g., chronic obstructed pulmonary disease and asthma) and diabetes Source: Health Advances analysis; 1 PharmaProjects (accessed February 2016); 2 WHO Mortality Database (accessed February 2016); 3 PhRMA 2015 Pharma Profile 9
10 BIOPHARMACEUTICAL COMPANIES HAVE MADE CONTINUED ADVANCES AGAINST RARE DISEASES There are approximately 7,000 different rare diseases worldwide 1 in 10 individuals in the USA and Europe are living with a rare disease 1 There are 119 OMPs authorised in the EU A-alimentary tract & metabolism B - blood & blood forming organs C - cardiovascular system D - dermatology G - genito urinary tract H - systemic hormonal preparations J & P - antiinfectives & antiparasitic L - antineoplastic agents L - immunomodulating agents M & N - musculoskeletal & nervous system R - respiratory system S - sensory organs V - various Distribution of Opinions by Therapeutic Area from Year Total Opinions 1,430 7% 12% 6% 5% 2% 36% 11% 7% 3% 5% 2% 1% 3% Rare Disease Big Impact Source: Health Advances analysis; 1 PhRMA 2013 Rare Diseases Report Source: Alexis Schimmings, New active substances launch plummet, Scrip Intelligence Unit. Available at: 10
11 TAIPEI, TAIWAN THE CHALLENGE 11
12 THE BIOPHARMACEUTICAL RESEARCH AND DEVELOPMENT PROCESS From drug discovery to EMA approval, developing a new medicine on average takes at least 10 years Basic Research Drug Discovery Pre- Clinical Clinical Trials EMA Review Post-Approval Research and Monitoring Post-Approval Research and Monitoring Phase 1 Phase II Phase III Phase IV 1 EMA- APPROVED MEDICINE POTENTIAL NEW MEDICINES Note: *The average R&D cost required to bring a new, FDA approved medicine to patients is estimated to be $2.6 billion over the past decade (in 2013 dollars), including the cost of the many potential medicines that do not make it through to FDA approval Key: IND: Investigational New Drug Application, NOA: New Drug Application. BLA: Biologics License Application Source: PhRMA 2016 Prescription Medicines: Costs in Context 12
13 COMPLEXITY OF THE REVIEW PROCESS Source: EuroStat ( Population of 501,103,425 as of 1 January
14 DIFFERENCES IN NATIONAL REIMBURSEMENT REVIEW PROCESSES LEAD TO VARIATIONS IN TIME TO ACCESS Average Time to National Patient Access to Necessary Therapeutics Months Post Approval Approval Limited Patient Access to Innovative Medicines Note: Timelines for EU5 countries are based on products with first sales in Timelines for Spain, Italy, UK, and France represent time to pricing and reimbursement approval. In Italy and Spain, additional time may be required for regional or local negotiations. Timeline for Japan may range from 2-3 months, and represents a conservative estimate based on publicly-available descriptions of the pricing and reimbursement approval process. Switzerland s separate regulatory approval may take at least 4-5 additional months after submission by manufacturer over timeline above. Norway is also not in EU and will need to formalize the EU approval, which may take at least 1 additional month. Source: Health Advances analysis; 1 ANSM 2014 Annual Report; 2 MHRA March 2015 EAMS Scientific Opinion for pembrolizumab 14
15 BOSTON, MASSACHUSETTS TEMPORARY FIXES? 15
16 REGULATORY Conditional marketing authorisations Marketing authorisations under exceptional circumstances Not used to their full potential 16
17 Source: Presentation by European Commission, Olga Salomon, STAMP meeting of May
18 NATIONAL EARLY ACCESS PROGRAMMES Source: ISPOR 15th Annual European Congress, Berlin, Germany, November 3-7, Poster ref: PHP147 18
19 NATIONAL EARLY ACCESS PROGRAMMES, CONT. Source: ISPOR 15th Annual European Congress, Berlin, Germany, November 3-7, Poster ref: PHP147 19
20 ETA/ETR: WHAT IS IT? Belgium ETA: Early Temporary (market) Authorization Early: Can be asked before obtaining regular MA No limits concerning moment of application Temporary: Limited in time Expires when replaced by regular MA How? CU/MNP evaluated by FAGG/AFMPS Draft royal decree changes rules on CU/MNP in general Source: pharma.be internal presentation 20
21 ETA/ETR: WHAT IS IT? Belgium ETR: Early Temporary Reimbursement Early: Must be asked before one can ask for regular reimbursement Can be asked even before regular MA At the earliest: 6 m. before application for regular MA Temporary: Limited in time (4 y. max.) Does not replace regular reimbursement procedure Not possible when one can apply for regular reimb. (CHMP adv.) Obligation to ask regular reimb. 6 m. after moment that one can introduce regular reimbursement application Expires when replaced by regular reimbursement Source: pharma.be internal presentation 21
22 BERLIN, GERMANY THE CASE FOR CHANGE 22
23 TODAY MORE THAN 7,000 MEDICINES ARE IN DEVELOPMENT AROUND THE WORLD TARGETING AREAS OF HIGH UNMET NEED Medicines in Development Worldwide 2,000 1,813 1,500 1,329 1,256 1,120 1, Cancers Neurological Disorders Infectious Diseases Immunological Disorders Cardiovascular Disorders Mental Health Disorders Diabetes HIV/AIDS Biopharmaceutical companies are focusing on areas of high unmet need Biopharmaceutical companies have made significant gains in key disease areas Note: Defined as single products which are counted exactly once regardless of the number of indications pursued. Source: Health Advances analysis; Adis R&D Insight Database HIV/AIDS is now a manageable, chronic disease, thanks to prior advances in biopharmaceutical research 23
24 DISEASE DIAGNOSIS ENABLES A TARGETED APPROACH TO PERSONALISED MEDICINES The evolution of molecular characterization and targeted therapeutics has led to a decrease in the average lung cancer death rate in the United Kingdom by 37% since 1980 Age-standardized death rates per 100,000 world standard population over time deaths per 100, deaths per 100, deaths per 100, deaths per 100, Adenocarcinoma KRAS Undefined KRAS EGFR Undefined ALK HER2 PI3K KRAS EGFR Undefined 0 identified 1 identified 5 identified 12 identified ALK HER2 ROS1 BRAF RET MEK PI3K MET NRAS AKT1 Identified Mutations/Rearrangements over Time 2,3 Note: WHO Mortality Database age-standardized death rates per 100,000 for malignant neoplasm of trachea, bronchus and lung. Source: Health Advances analysis; 1 WHO Mortality Database (accessed February 2016); 2 My Cancer Genome website Molecular Profiling of Lung Cancer; 3Pao 2012 Chipping away at the lung cancer genome Nat Med. 24
25 MEDICINES OFTEN DEMONSTRATE FAR GREATER BENEFITS THAN UNDERSTOOD AT TIME OF APPROVAL Oncology therapeutics demonstrate increasing clinical value over time long after initial approval Use in earlier lines of treatment and earlier in stages of the disease Use in additional disease indications Use in combination with other agents Use in combination with specific biomarkers Year 4: Additional Indication Mantle Cell Lymphoma (MCL) Second Line Year 6: Approved for Use Earlier in Line of Treatment MM First Line Year 11: Approved for Use Earlier in Line of Treatment MCL First Line Year 1: Initial Approval Multiple Myeloma (MM) Third Line Year 3: Approved for Use Earlier in Line of Treatment MM Second Line Additional Patients Benefiting Added Clinical Value Over Time Note: Representation of the change in clinical value over time in the US as additional data and evidence became available for Bortezomib Source: Health Advances analysis; Boston Healthcare Assoc The Value of Innovation in Oncology 25
26 MEDICINES OFTEN DEMONSTRATE FAR GREATER BENEFITS THAN UNDERSTOOD AT TIME OF APPROVAL Many cancer medicines provide years of extra life but media attention is often focused on soon after launch and/or in late stage patients before it has had the chance to prove long-term value. Metastatic use Adjuvant use Oncology medicines typically launched only in metastatic setting. (i.e., very sick patients that have failed on other therapies with poor prognosis) Measured outcomes for such patients by definition will be relatively poorer Once an oncology medicine is more established it can be used in an adjuvant setting (i.e., patients with a better prognosis before tumours have spread) Measured outcomes, by definition for such patients often better than patients whose cancer is more advanced Early assessment can show relatively poor value for money but such static assessments do not reflect value over the lifecycle Often prices that were seen as high when initially assessed are seen as highly cost effective by the time a medicine is in adjuvant use Important to consider value over the lifecycle 26
27 A LONGER-TERM VIEW 27
28 ADAPTIVE PATHWAYS: WHY? To address an unmet need To overcome difficulties in following a conventional development plan To increase the B/R To decrease the time of uncertainty To plan the evidence generation Source: Guido Rasi, HTAi Annual Meeting, May
29 THE ADAPTIVE PATHWAYS CONCEPT: ITERATION 1) Conditional approval scenario Knowledge required for full approval 1st approval 2nd approval AP route 2) Expansion of indication scenario AP route Source: EMA slide at Commission expert group on rare diseases, November
30 EXISTING SUPPORT TOOLS FOR ADAPTIVE PATHWAYS During development Joint or parallel early dialogue or advice offered by Regulatory Agencies and/or HTA Marketing authorisation* Approval in sequential stages (e.g., using conditional approval, post-approval safety and efficacy studies, risk management plans, periodic safety update reports, license renewal procedures) Post-approval Gathering evidence through real-life use to supplement clinical trials data *MAPPs does not change the standards for the evaluation of the benefit/risk balance required to grant a marketing authorisation from a quality, safety and efficacy point of view. Source: Presentation by A Joos / M Boudes / JL Roux, Adapt Smart multi-stakeholder workshop on selection criteria, 29 February, Amsterdam 30
31 IMPLICATIONS BEYOND REGULATORY Joint scientific advice (SA) Joint process or parallel early for dialogue design or of advice randomised offered by controlled trials (RCTs) and Regulatory other Agencies studies and/or HTA During development Iterative HTA recommendations, Approval in starting sequential stages, with e.g. European using conditional Relative approval, post-approval safety and efficacy studies, risk Efficacy Assessment (EU management REA) at time plans, periodic of launch safety update and followed reports, license by Managed Entry Agreements renewal (MEA) procedures Marketing authorisation* Joint scientific advice (SA) process for design of randomised Post-approval controlled trials (RCTs) and other studies Gathering evidence through real-life use to supplement Clinical Trials data *MAPPs does not change the standards for the evaluation of the benefit/risk balance required to grant a marketing authorisation from a quality, safety and efficacy point of view. 31
32 HTA V Regulators % agreement MAKING THE CASE 56 products Population Endpoints Comparator Recommendation Source: Guido Rasi, HTAi Annual Meeting, May
33 HTA V Regulators % agreement CAN PARALLEL ADVICE HELP? Commonality? Population Endpoints Comparator Overall Package Source: Guido Rasi, HTAi Annual Meeting, May 2016 Parallel Advice DIA EuroMeeting 33
34 ITERATIVE HTA REC. INDUSTRY VIEWS At launch Based on European joint relative efficacy assessment (EU REA) fully integrated into a comprehensive national HTA EU REA based on randomised controlled trial (RCT) data discussed in joint scientific advice (SA) process Supporting initial pricing and reimbursement decision 34
35 EU REA report Local considerations Decision-maker Description of the health problem Local issues related to the health problem The technology & its place in treatment pathway Local treatment pathway Relative Efficacy Appraisal recommendation Local coverage decision Relative Safety Key Economic considerations Joint Local Social values / ethical & legal issues 35
36 ITERATIVE HTA REC. INDUSTRY VIEWS Over time Subsequent national HTA based on additional evidence generation Feeding into managed entry agreements (MEA) These questions can be answered based early evidence from Phase I and Phase II studies Source: HTAi 2016 Annual Meeting, Tokyo, Japan 36
37 EXPERIENCE OF MEAS IN THE CONTEXT OF CMA Out of the 17 products with conditional approval or approval under exceptional circumstances which were discussed on our interviews, only 9 products were reported to have been subject to some form of MEA (both financial and outcomes based or a mix) 5 reported cases of financial agreements Subject to outcome-based agreements 4 reported cases of outcome-based agreements for oncology products (across 3 different countries) Oncology (no OMP) 6 5 We did not find outcomes-based agreements for orphan medicinal product (OMP) with CMA Oncology OMP Orphan Medicinal Product 6 There was a consensus amongst OMP manufacturers that given small patient pop. and the administration cost involved, outcomes-based scheme for orphan drugs were not warranted Subject to financial agreements Source: CRA report on MEA for CMA products Given high level of uncertainty and greater patient population, oncology products (without OMP status) with CMA appear to be more likely to be subject to outcomes-based MEA 37
38 DATA REQUESTED BY REGULATORS VS. PAYERS FOR PRODUCTS WITH CMA SUBJECT TO OUTCOMES-BASED MEAS Product Therapy area CMA Data request by EMA Type of MEA Payer data requested Product 1 Oncology mrcc Conditional Approval Review of Phase III data Conditional reimbursement (Czech republic) Not specified Product 2 Oncology NSCLC Conditional Approval Information on patient population for proof of epidemiology-eligible patient population. Phase IV trial was conducted Conditional reimbursement (Poland) Local clinical & epidemiological data (to support the reimbursement application (e.g., drawing data from electronic medical records) Product 3 Oncology CML Conditional Approval A larger study on specific patients sub population previously treated with one or more tyrosine-kinase inhibitors Conditional reimbursement (Sweden) Uncertainty in the clinical efficacy for the indicated patient population due to lack of clinical trial information Product 4 Oncology BCC Conditional Approval Additional safety study in specific patients sub population Combination of discounts & payment-by-result (Italy) Concerns on the safety and efficacy - requested additional safety data for specific sub populations Metastatic renal cell carcinoma (mrcc); non-small cell lung cancer (NSCLC); Chronic myeloid leukaemia (CML); Advanced Basal Cell Carcinoma (adv BCC) Source: CRA report on MEA for CMA products 38
39 WHAT IS NEEDED TO ENSURE MEAS CAN SUPPORT ADAPTIVE PATHWAYS? AN INDUSTRY PERSPECTIVE Alignment of data requirements between payers and regulator could mean that improved evidence development for MAPPs could mean greater use of outcomes-based agreements If there was the possibility to do so, many companies indicated they would be keen to explore such opportunities (as this allows price to reflect data on the value of the product) This is especially relevant in oncology products where effectively measuring health outcomes and determining clinical end points is becoming more and more relevant In today s context it is perhaps less so for orphan medicines considering the current transaction costs involved in developing additional data collection mechanism on low numbers of patients In this case there would be value in EMA coordinating with payers/htas about the additional real-world data evidence requirements This would then provide a signal for local/regional registries and regional coordinators to collect the required data with the simplest method possible 39
40 TAIPEI, TAIWAN SUPPORTIVE ACTION 40
41 PUBLIC PRIVATE PARTNERSHIP IMI Address Bottlenecks of Innovation Industry consortium IMI office = Neutral broker Process owner EU Commission In-kind contribution Value of companies' contribution = EU funding available for public partners FTEs + cash In kind translated into EU Commission matches the industry contribution Total project budget 41
42 MAPPS AND ADAPT-SMART MAPPS (Medicines Adaptive Pathways to Patients) is a concept that, based on scientific advances, seeks to provide timely access to medicines with potential to address unmet need(s) in specific, well-defined patient populations, in a sustainable way MAPPs cover development and regulatory approval, HTA value assessment, pricing/reimbursement decisions, and access MA and reimbursement/access decisions are made using a framework which supports the launch of a therapy based on early initial evidence Data generated post-marketing Authorisation should support progressive decrease of benefit/risk uncertainty and may lead to adjustment(s) in use, in response to the emerging RWE and eventual supplemental clinical trial data ADAPT-SMART is an IMI2 Coordination and Support Action (CSA - running to end 2017) investigating and exploring conditions and feasibility of the MAPPS concept within the current EU regulatory/legal context 42
43 HOW WOULD SUCCESS FOR ADAPT-SMART LOOK? (FROM AN INDUSTRY VIEW-POINT) Aligned understanding by all stakeholders How a better planned development would enable the earliest possible and sustainable access for specific novel and promising medicines in welldefined patient groups, including post-marketing Authorisation data gathering/reporting and review What is the balance of prospectively planned Randomised Controlled Trials and trials based on routinely collected evidence (Real-World Evidence) in well-defined patient populations in adaptive pathways Effective, open platform for dialogue with all stakeholders on all questions Operational predictability for companies (big and small): Road map on MAPPs criteria/tools, on methodologies/timelines, on the stakeholders to be involved at every step, and on data requirements/standards Understanding on how adaptive pathways fit in a global development framework Setting up mechanisms for continued engagement post-adapt-smart, based on its outcome(s) 43
44 GET REAL: OUR GOAL To show how real-world evidence can be adopted in medicine development and healthcare decision making and provide the tools required to achieve this. Software Patient and methodology data Case studies Clinical trials Network analysis Identifying the efficacy effectiveness gap and signalling solutions Innovative approaches to study design and analytics Analytical software Toolboxes and framework Guide study design Inform decision making Real-World Evidence Navigator to guide strategy, design, and interpretation by all stakeholders PragMagic to guide pragmatic trial implementation Support HTA interpretation Educate Education and Policy training Education of stakeholders HTA and end users in the use and implications of Real- R&D World Evidence is key to ensure the legacy of GetReal Academia Industry 44
45 GET REAL: OUR GOAL To show how real-world evidence can be adopted in medicine development and healthcare decision making and provide the tools required to achieve this. Patient data Guide study design Inform decision making Policy Case studies Network analysis HTA R&D Academia Clinical trials Support HTA interpretation Educate Industry 45
46 IMI BIG DATA FOR BETTER OUTCOMES (BD4BO) Goal: Support the evolution towards outcomes-focused and sustainable healthcare systems, exploiting the opportunities offered by big and deep data sources in COORDINATION AND SUPPORT ACTION (CSA) EUROPEAN DISTRIBUTED DATA NETWORK Design sets of standard outcomes and demonstrate value Increase access to high quality outcomes data Use data to improve value of HC delivery Increase patient engagement through digital solutions ROADS: ALZHEIMER'S DISEASE HEMATOLOGIC MALIGNANCIES CARDIOVASCULAR DISEASES RARE CANCERS... ADDITIONAL TOPICS... 46
PhRMA Days Press Conference
PhRMA Days Press Conference April 12, 2017 Joaquin Duato Chairman of the Board, PhRMA Roadmap I. Recent Developments in the United States II. Biopharmaceutical Industry s Contribution to Innovation and
More informationHTAs and EMA working together: 23 parallel scientific advice procedures later - what have we learned?
HTAs and EMA working together: 23 parallel scientific advice procedures later - what have we learned? DIA 26th Annual EuroMeeting, Vienna 2014 Jan Regnstrom, MD, PhD Senior Scientific Officer An agency
More informationUse of RWE in a regulatory context: issues and examples. Rob Hemmings, MHRA
Use of RWE in a regulatory context: issues and examples Rob Hemmings, MHRA Disclaimer I don t particularly like the terms real world data, real world evidence. To be more precise, I will discuss data generated
More informationEMA Adaptive licensing: a tool concept for accelerated access to innovative medicines? Rob Hemmings, MHRA
EMA Adaptive licensing: a tool concept for accelerated access to innovative medicines? Rob Hemmings, MHRA Slides largely re-produced from a previous EMA presentations to (DIA, Paris; STAMP, Brussels).
More informationEuropean contribution to the RWD/RWE debate. Alasdair Breckenridge July 2018
European contribution to the RWD/RWE debate Alasdair Breckenridge July 2018 Sources UK Academy of Medical Sciences(AMS) workshops European Medicines Agency (EMA) Innovative Medicines Initiative (IMI) projects
More informationIMI2: Strategic research agenda and overall approach Hugh Laverty Senior Scientific Project Manager
IMI2: Strategic research agenda and overall approach Hugh Laverty Senior Scientific Project Manager Introducing IMI2: Vienna 16 July 2014 The way in which pharmaceutical companies develop new medicines
More informationFrom innovation to outcomes; medicines costs in context. Author: Andrew Powrie-Smith * Date: 20/04/2016 * Version: FINAL. Pricing.
From innovation to outcomes; medicines costs in context Author: Andrew Powrie-Smith * Date: 20/04/2016 * Version: FINAL Pricing About this deck The Medicines Costs in Context slide deck has been developed
More informationagenda The Path to Market for New Medicines The Association of the British Pharmaceutical Industry (ABPI)
Note: Dates of innovation provided by the US Food and Drug Administration (FDA). Source:Health Advances analysis; PhRMA 2015 pharmaceuticals in Perspective. agenda The Path to Market for New Medicines
More informationEU Big Data Initiatives
European Network of Excellence for Big Data in Hematology, consisting of 51 partners from 11 countries. Aliki Taylor, HARMONY Alliance Partner Director Global Health Outcomes, Takeda EU Big Data Initiatives
More informationRegulatory point of view on clinical benefit assessment and parallel EMA/HTA advice
Regulatory point of view on clinical benefit assessment and parallel EMA/HTA advice Ateliers de Giens Meeting - French Society of Pharmacology and Therapeutics - Paris, March 23rd 2016 An agency of the
More informationNew Ways to Source Innovation in the Healthcare Industry In-licensing needs Oncology of Janssen/Johnson & Johnson Innovation
New Ways to Source Innovation in the Healthcare Industry In-licensing needs Oncology of Janssen/Johnson & Johnson Innovation Dr. Klaus Suwelack Johnson & Johnson Innovation, Janssen-Cilag Germany, Neuss
More informationEMA - Early Access. PEARRL Annual Meeting 2017-Regulatory Science Symposium. University College Cork, Ireland
EMA - Early Access PEARRL Annual Meeting 2017-Regulatory Science Symposium University College Cork, Ireland Presented by Evangelos Kotzagiorgis Scientific Administrator, Quality of Medicines Office Specialised
More informationInnovative Medicines Initiative
Innovative Medicines Initiative EMA - EBE Regulatory Conference on ATMPs Salah-Dine Chibout, Novartis Global Head Discovery & Investigative Safety/ Global Head Preclinical Safety Therapeutic Areas IMI
More informationNew WHO Report: Access to new medicines in Europe: Technical review of policy initiatives and opportunities for collaboration and research
New WHO Report: Access to new medicines in Europe: Technical review of policy initiatives and opportunities for collaboration and research Hanne Bak Pedersen Programme Manager Health Technologies and Pharmaceuticals
More informationEUROPEAN COMMISSION DIRECTORATE-GENERAL FOR HEALTH AND FOOD SAFETY
EUROPEAN COMMISSION DIRECTORATE-GENERAL FOR HEALTH AND FOOD SAFETY Health systems, medical products and innovation Medicines: policy, authorisation and monitoring STAMP 4/24 Record STAMP Commission Expert
More informationUse of Real World Data in Development Programmes
Use of Real World Data in Development Programmes Dr Alison Cave and Dr Francesca Cerreta Industry Stakeholder Platform on Research and Development Support 25 April 2017 An agency of the European Union
More informationDrugs, medical progress,
Drugs, medical progress, and the road ahead Scott Gottlieb, MD Resident Fellow The American Enterprise Institute Page 1 The Pharmaceutical Industry s Market Global Pharmaceutical Sales, by Region (in billions
More informationFollowing Cancer Drug Pathways from Inception to Launch: Partnership, prospects and Pitfalls. Katie Pascoe (Value and Access, ABPI) 22 September 2016
Following Cancer Drug Pathways from Inception to Launch: Partnership, prospects and Pitfalls Katie Pascoe (Value and Access, ABPI) 22 September 2016 Partnering is a key factor in patient access to new
More informationRWE from pre-clinical to launch. RWE from pre-clinical to launch. Standard of care Unmet needs. Disease burden Budget impact.
Real Real World World Data Data Across Across the the Product Product Lifecycle: Lifecycle: RWE from pre-clinical to launch RWE from pre-clinical to launch Standard of care Unmet needs Disease burden Budget
More informationOrphan Medicines Figures
Orphan Medicines Figures 2000-207 Orphan Medicines - Product Development Scientific Support An agency of the European Union Applications for orphan medicinal product designation 2000 2006 20 206 207 Total
More informationFDA Critical Path Initiative: Closing Productivity Gap in Medical Product Development. October 4, 2004
FDA Critical Path Initiative: Closing Productivity Gap in Medical Product Development October 4, 2004 1 What is the problem? Trends in Biomedical Research Spending R&D Spending Has Accelerated Since 1990
More informationPersonalised Medicine Regulatory Issues
Personalised Medicine Regulatory Issues INFRAFRONTIER / IMPC Stakeholder Meeting Presented by Marisa Papaluca on 14 November 2017 Senior Scientific Advisor, Scientific Committees Regulatory Science Strategy
More informationBD4BO and ROADMAP: a collaborative approach to set new standards for the collation and evaluation of RWE in Alzheimer s Disease
BD4BO and ROADMAP: a collaborative approach to set new standards for the collation and evaluation of RWE in Alzheimer s Disease Impact of Big Data Analytics on Healthcare 4-5 October 2017, Luxembourg Dr
More informationThe Role of Public-Private Partnerships & Evidence Generation
The Role of Public-Private Partnerships & Evidence Generation Christina Donatti LLB, BSc, MSc, PsyD IMI Lead, RWE EMEA Strategic Organisation. Janssen Cilag Janssen is proud to feature artwork created
More informationUniversità Cattolica del Sacro Cuore
Università Cattolica del Sacro Cuore The role of Regulatory Affairs in drug development Francesco Mazza, Director of Legal, Fiscal & Compliance Affairs in Farmindustria Rome, May 12 2017 Who we are Who
More informationABPI response to European Commission consultation on advanced therapy medicinal products
ABPI response to European Commission consultation on advanced therapy medicinal products 28 March 2013 ABPI response to European Commission consultation on the regulation of advanced therapy medicinal
More informationBelgium, a European leader in clinical trials
Belgium, a European leader in clinical trials An attractive country for clinical trials to test innovative medicines In Europe it is nearly impossible to find other countries with as many clinical trials
More informationStrengthening the prospective discussions on post-licensing evidence generation
Strengthening the prospective discussions on post-licensing evidence generation Industry stakeholder platform on research and development support Presented by Jane Moseley on Senior Scientific Officer
More informationOrphan Medicinal Products
Development process of Orphan Medicinal Products 1 Did you know that... A rare disease is officially defined as a lifethreatening or chronically debilitating condition that affects no more than 5 in 10,000
More informationEFPIA POSITION PAPER THE EFPIA SURROGATE ENDPOINT INITIATIVE
EFPIA POSITION PAPER THE EFPIA SURROGATE ENDPOINT INITIATIVE EMEA/EFPIA Workshop on Biomarkers London 15 December 2006 Solange Corriol-Rohou Rohou,, MD ERAD AstraZeneca 1. Current situation Topics for
More informationDrug Spending % of Healthcare Spending DRUG SPENDING % OF HEALTHCARE SPENDING 20% 15% 10% 5% 0% 1995 2000 2005 2010 2015 Japan, 15.0% France, 9.8% US Net, 9.8% UK, 9.7% Germany, 9.0% France Germany Japan
More informationWorkshop on Access to and Uptake of Biosimilar Medicinal Products
EUROPEAN COMMISSION Directorate-General for Internal Market, Industry, Entrepreneurship and SMEs Consumer, Environmental and Health Technologies Biotechnology and Food Supply Chain Workshop on Access to
More informationAlliance for Regenerative Medicine
Alliance for Regenerative Medicine Michael Werner Executive Director Alliance for Regenerative Medicine ARM s Focus & Role As the leading global advocate for the regenerative medicine and advanced therapies
More informationInnovative Medicines Initiative (IMI) Future funding opportunities. Catherine Brett, IMI Conferencia H2020 y Salud Madrid, Spain 8 November 2017
Innovative Medicines Initiative (IMI) Future funding opportunities Catherine Brett, IMI Conferencia H2020 y Salud Madrid, Spain 8 November 2017 Outline What is IMI and why do we need it? How does IMI work?
More informationEU regulatory tools for expedited antibacterial development programmes
EU regulatory tools for expedited antibacterial development programmes Expediting antibacterial development: core lessons key tools for a rocky road, ECCMID 2018, Madrid Presented by Marco Cavaleri on
More informationPhRMA. Annual Press Conference
PhRMA Annual Press Conference February 1, 2017 Patrik Jonsson Chairman of Japan Based Executive Committee PhRMA Japanese Policy Changes Have Fostered Patients' Access to New Medicines Thanks to the transformation
More informationEarly Engagement: One Stop Shop
Early Engagement: One Stop Shop Indranil Bagchi, Ph.D. Vice President, Payer Insights & Access April 7, 2014 Insert presentation title, GH&V tagline, you and your groups name and date What is Early Scientific
More informationMoving HTA forward: The challenges of incorporating real world evidence into Health Technology Assessment
Moving HTA forward: The challenges of incorporating real world evidence into Health Technology Assessment Matthias Egger Mike Chambers Univ. of Berne, Switzerland GSK, UK Slide 1 Increasingly complex external
More informationMay 9, Creating a Successful Global Value Dossier
May 9, 2018 Creating a Successful Global Value Dossier Anne Heyes Head Market Access and Outcomes Strategy (Europe) Stephanie Barrows Senior Director Market Access and Outcomes Strategy Caroline Ling Senior
More informationFinal report on the adaptive pathways pilot
28 July 2016 EMA/276376/2016 European Medicines Agency Summary In March 2014 EMA launched a pilot project to explore the adaptive pathways approach, a scientific concept of medicines development and data
More informationPrescription Medicines: Costs in Context
Prescription Medicines: Costs in Context 2018 We are in a new era of medicine where breakthrough science is transforming care with innovative treatment approaches... Then Now Medicines made of chemical
More informationThe role of patients at the EMA
The role of patients at the EMA Nathalie Bere Patient relations coordinator / European Medicines Agency An agency of the European Union What is the European Medicines Agency (EMA) The EMA is the EU regulatory
More informationProof of Concept. Achieve your molecule s full potential
Proof of Concept Achieve your molecule s full potential Table of contents 01 Maximize the value of your molecule 02 Enhance your resources and 03 Increase your speed and efficiency 04 your product s market
More informationUse of immunotherapy for cancer treatment
Use of immunotherapy for cancer treatment Pre- and post-licensing considerations Professor Angela Thomas, Pediatric Hematologist Vice Chair Commission on Human Medicines Chair Clinical Trials, Biologicals
More informationEarlier Access to Medicines Early Access to Medicines Scheme and Adaptive Licensing pilot
Earlier Access to Medicines Early Access to Medicines Scheme and Adaptive Licensing pilot World Stem Cells & Regenerative Medicine 2014 Dr Daniel O Connor Disclaimer The views expressed do not necessarily
More informationDETERMINANTS OF ORPHAN DRUG PRICES IN FRANCE: REGRESSION ANALYSIS
DETERMINANTS OF ORPHAN DRUG PRICES IN FRANCE: REGRESSION ANALYSIS Korchagina D 1, Vataire AL 2, Toumi M 3, Falissard B 4, Aballéa S 2 ISPOR 18th Annual European Congress 1 University of Paris-Sud, Paris,
More informationPrescription Medicines: Costs in Context
Prescription Medicines: Costs in Context 2018 We are in a new era of medicine where breakthrough science is transforming care with innovative treatment approaches... Then Now Medicines made of chemical
More informationRole of drug regulation (if any )
Health, Growth and Finance Brescia 17 th June 2016 Role of drug regulation (if any ) Presented by Guido Rasi Executive Director, European Medicines Agency An agency of the European Union Mandate of EMA
More informationCoordination and Support Action (CSA) for the Big Data for Better Outcomes programme. Stephan Korte, Kim Cryns
Coordination and Support Action (CSA) for the Big Data for Better Outcomes programme Stephan Korte, Kim Cryns 11.01.2016 IMI webinar Big Data for Better Outcomes (BD4BO) Initiative within IMI2 Goal Support
More informationEU scientific regulatory support mechanisms and initiatives for innovation in drug development: the EMA perspective
EU scientific regulatory support mechanisms and initiatives for innovation in drug development: the EMA perspective FAMHP Workshop, Brussels, 2 nd May 2016 Presented by Zahra Hanaizi Product Development
More informationOrphan Medicines Figures
Orphan Medicines Figures 000-05 Orphan Medicines - Product Development Scientific Support An agency of the European Union Status of Orphan Applications 000 005 006 00 0 0 03 04 05 Total Applications submitted
More informationReport from the Paediatric Committee on its first anniversary
European Medicines Agency London, 11 July 2008 Doc. Ref. EMEA/PDCO/347884/2008 Report from the Paediatric Committee on its first anniversary The European Medicines Agency s Paediatric Committee (PDCO)
More informationA LEADER IN SPECIALTY CARE
A LEADER IN SPECIALTY CARE Zi Qing, Pompe Disease, Taiwan SCIENCE-DRIVEN, PATIENT-FOCUSED Patients and science are at the center of everything we do, defining and uniting our efforts across rare diseases,
More informationAccelerated Development of Appropriate Patient Therapies
Accelerated Development of Appropriate Patient Therapies A Sustainable, Multi-stakeholder Approach for MAPPS - Medicines Adaptive Pathways to Patients André Broekmans Coordinator Adapt Smart Work Package
More informationDatamonitor Healthcare Pharma intelligence informa Datamonitor Healthcare Content Calendar
Datamonitor Healthcare 2017 Datamonitor Healthcare Content Calendar 2017 Content Calendar Published February 2017 Datamonitor Healthcare provides up-to-date insights and analysis that you can trust. Disease
More information6th EUROPEAN CONFERENCE ON RARE DISEASES & ORPHAN PRODUCTS ECRD 2012 Brussels
www.eurordis.org 6th EUROPEAN CONFERENCE ON RARE DISEASES & ORPHAN PRODUCTS ECRD 2012 Brussels Brussels, 24-25 May 2012 www.eurordis.org THE NEW PARADIGMS OF RARE DISEASES TREATMENT DEVELOPMENT & ACCESS
More informationCoordination and Support Action: Enabling platform on medicines adaptive pathways to patients
Coordination and Support Action: Enabling platform on medicines adaptive pathways to patients Solange Rohou (AZ) & Luk Maes (BMS) 17.12.2014 IMI webinar Content Background information CSA project proposal
More informationPrescription Medicines: Costs in Context
Prescription Medicines: Costs in Context 2017 We are in a new era of medicine where breakthrough science is transforming care with innovative treatment approaches... Then Now Medicines made of chemical
More informationAIFA s post-marketing registries and accelerated patient access. Opportunities and challenges in the context of MAPPs
AIFA s post-marketing registries and accelerated patient access. Opportunities and challenges in the context of MAPPs Entela Xoxi Can RWD accelerate patient access to medicines? London, 7th July 2016 Since
More informationThe Innovative Medicines Initiative Europe s partnership for health. Tek-Ang LIM, 20 June 2018, Brussels
The Innovative Medicines Initiative Europe s partnership for health Tek-Ang LIM, 20 June 2018, Brussels 10 YEARS OF LIGHTING THE WAY IMI Why Europe s partnership for health? Because despite decades of
More informationBIOPHARMACEUTICAL BUSINESSES
BIOPHARMACEUTICAL BUSINESSES Our Biopharmaceuticals businesses consist of four patientcentric, customer-facing business units. The business units are responsible for further clinical development and lifecycle
More informationThis video gives an overview of the centralised procedure at the European Medicines Agency
This video gives an overview of the centralised procedure at the European Medicines Agency In Europe today, all medicines must have a marketing authorisation before they can be used by patients And there
More informationUsing local RWD to drive global therapeutic advancements.
Using local RWD to drive global therapeutic advancements. Helsinki, 30 th Nov 2016 Mike Spencer, Head of Real World Evidence, EMEA, Janssen The following represent my own views and not necessarily those
More informationFrom IMI to IMI2 new models of collaborative research. Magda Chlebus, Science Policy, EFPIA Ljubljana, 23 May 2014
From IMI to IMI2 new models of collaborative research Magda Chlebus, Science Policy, EFPIA Ljubljana, 23 May 2014 What is IMI and how does it work? Innovative Medicines Initiative: Joining Forces in the
More informationPrescription Medicines: International Costs in Context. March 2017
Prescription Medicines: International Costs in Context March 2017 PART 1: Medicines Benefit Patients, Health Care Systems, and Economies Medicines Benefit Patients, Health Care Systems, and Economies Patients
More informationTopic: Genome-Environment Interactions in Inflammatory Skin Disease
Topic: Genome-Environment Interactions in Inflammatory Skin Disease All information regarding future IMI Call topics is indicative and subject to change. Final information about future IMI Calls will be
More informationUK Early Access to Medicines Scheme (EAMS) an Examination. Manager, PLAT 5 May 2017
UK Early Access to Medicines Scheme (EAMS) an Examination Sue Harris London Manager, PLAT 5 May 2017 Crown copyright 2013 About copyright All material created by the Medicines and Healthcare Products Regulatory
More informationPartnering & Networks
Partnering & Networks Success drivers in an ever changing and complex health care system Dr. Benedikt Hoffmann, Senior Manger New Business Development & J&J Innovation Manager October 2 nd, 2014 Judith
More informationEBE White Paper on Personalised Medicine
EBE White Paper on Personalised Medicine EBE is a specialised group of European Federation of Pharmaceutical Industries and Associations, EFPIA Content p3 p4 p6 p6 p7 p9 p10 p11 p13 p14 Executive Summary
More informationADVANCE MEDICINE. AstraZeneca Japan President Stefan Woxström shares his healthcare vision. By C Bryan Jones
ADVANCE MEDICINE AstraZeneca Japan President Stefan Woxström shares his healthcare vision By C Bryan Jones Biopharmaceutical company AstraZeneca says science is at the heart of everything they do. With
More informationBiotechnology Certificate New Technologies For Health
Weekly Barometer 25 janvier 2012 Biotechnology Certificate New Technologies For Health April 2017 ATONRÂ PARTNERS SA 12, Rue Pierre Fatio 1204 GENEVA SWITZERLAND - Tel: + 41 22 310 15 01 http://www.atonra.ch
More informationConditional marketing authorisation
Conditional marketing authorisation Report on ten years of experience at the EMA Presented by Zigmars Sebris on 27 June 2017 Regulatory Affairs Office, Human Medicines Evaluation Division An agency of
More informationUpdate on Real World Evidence Data Collection
Update on Real World Evidence Data Collection STAMP, 10 March 2016 Presented by Dr Peter Arlett EMA An agency of the European Union What is Real-world evidence? Big data = umbrella term describing large
More informationRegulatory Support to EU Research
Regulatory Support to EU Research OPEN INFO DAY Horizon 2020 'Health, demographic change and wellbeing Friday, 8 December 2017 Brussels Presented by Marisa Papaluca Senior Scientific Advisor, Scientific
More informationEMA/CAT support to ATMP developers
EMA/CAT support to ATMP developers CAT-ISCT Workshop: Challenge and opportunities for the successful development and approval of Advanced Therapy Medicinal Products. Presented by Patrick Celis on 25 September
More informationAccelerated Approvals
Accelerated Approvals An Industry Perspective Kumeshnie Padayachee University of Pretoria 09 September 2015 Table of Contents ZA Expedite Review Process Fast Track Overview of FDA Expedited Pathways: Focus
More informationInsights into the Evolving Pricing & Market Access Environment
Insights into the Evolving Pricing & Market Access Environment UBC Global Market Access Survey July 2012 JULY 2012 GLOBAL MARKET ACCESS SURVEY UBC s Global Market Access Survey: Setting the Stage For those
More informationNational Foundation for Women Legislators Annual Meeting September 12, 2015 Tara Ryan Vice President, State Government Advocacy
From Hope to Cures: The Value of Biopharmaceutical Innovation National Foundation for Women Legislators Annual Meeting September 12, 2015 Tara Ryan Vice President, State Government Advocacy HIV/AIDS: Then
More informationRegulatory update from Europe:
Regulatory update from Europe: Procedures to promote early access of medicinal products to the market Elmer Schabel MD Regulatory update from Europe - Overview Current tools for early access Conditional
More informationBiomarker Regulation. Regulator s perspective. Jan Müller-Berghaus
www.pei.de Biomarker Regulation Regulator s perspective Jan Müller-Berghaus The views presented here are my own and do not necessarily reflect the views of the Paul-Ehrlich-Institut or any other regulatory
More informationADAPTIVE PATHWAYS WORKSHOP
ADAPTIVE PATHWAYS WORKSHOP Stockholm Friday, November 10, 2017 9:00 13:00 Adaptive Pathways Applications for Scientific Insights in Europe PRESENTED BY: An ICON plc Company Agenda Overview 9:00 9:10 9:10
More informationThe compassionate use of medicinal products. An example: the French ATU system. 0ff label use in France
0 The compassionate use of medicinal products. An example: the French ATU system 0ff label use in France C. Bélorgey Head of Department of evaluation of Clinical Trials and medicinal products of special
More informationThe Context in which we operate
Prof. Sergio Pecorelli Presidente Agenzia Italiana del Farmaco Rettore Università degli Studi di Brescia The Context in which we operate Limited Resources Population Ageing Healthcare rights One single
More informationEU support for Health Research from FP6 to FP7
EU support for Health Research from FP6 to FP7 Stéphane Hogan Head of Biotechnology Unit Directorate for Health Research DG Research - European Commission Valencia - 15 September 2006 EU research programmes
More informationPublic private partnerships in support to regulatory sciences
Public private partnerships in support to regulatory sciences The Innovative Medicines Initiative example M. Chlebus 3 October 2017 www.efpia.eu Summary: Partnering on regulatory sciences Progress much
More informationRegulatory Challenges of Global Drug Development in Oncology. Jurij Petrin, M.D. Princeton, NJ
Regulatory Challenges of Global Drug Development in Oncology Jurij Petrin, M.D. Princeton, NJ Topics General global R&D issues Regulatory issues with global oncology drug development US FDA initiatives
More informationPrecision Medicine & Health Insurance Business Model Disruption? A Data& Evidence perspective
Precision Medicine & Health Insurance Business Model Disruption? A Data& Evidence perspective December 12 th, 2017 Dr. Tim Wintermantel Real World Insights Lead, Switzerland Copyright 2017 IQVIA. All rights
More informationRole of the FDA and PDUFA in Drug Development
Role of the FDA and PDUFA in Drug Development Questions to be addressed 1. What is the Food and Drug Administration and why is it important? 2. Why was the Prescription Drug User Fee Act (PDUFA) created?
More informationIssues identified by stakeholders: follow-up from EMA s ATMP workshop
2 February 2017 EMA/48099/2017 Human Medicines Research and Development Support Division On 27 May 2016 EMA hosted a workshop 1 aimed to foster ATMP development and enable expanded patient access in the
More informationThe Innovative Medicines Initiative. Pierre Meulien CNIO, Madrid - Spain
The Innovative Medicines Initiative Pierre Meulien 12.01.2017 CNIO, Madrid - Spain IMI Europe s partnership for health > 5 bn 2.5 bn Partnership 2008-2020 Pharma industry 2.5 bn EU contribution from FP7
More informationPRIME: a two-year overview
PRIME: a two-year overview Highlights 177 requests for eligibility to PRIME received and assessed since launch in March 2016. Number of requests has been fairly constant and have matched forecasts, with
More informationNews For Immediate Release
News For Immediate Release Contact: Gary Gatyas IMS Institute for Healthcare Informatics (610) 244-2600 ggatyas@us.imshealth.com IMS Study Forecasts Rebound in Global Spending on Medicines, Reaching Nearly
More informationHeadline Verdana Bold
Headline Verdana Bold Proposal for a study report on Belgium as clinical trial location in Europe Belgium as clinical trial location in Europe Presentation of results for 2016 4 May 2018 Methodology of
More informationInvestor Presentation. October 2018
Investor Presentation October 2018 Forward Looking Statements This presentation contains forward-looking statements. "Forward-looking statements," as that term is defined in the Private Securities Litigation
More informationInformation Day Leeds, UK 27 October 2015 Treating and managing disease
The societal challenge 'Health, demographic change and well-being' Work programme 2016-2017 Information Day Leeds, UK 27 October 2015 Treating and managing disease Image credit: Adam Fagen Rallying for
More informationHTA and managed entry practices in Europe - Pharmaceutical industry perspective. Edith FRENOY Director Market Access EFPIA
HTA and managed entry practices in Europe - Pharmaceutical industry perspective Edith FRENOY Director Market Access EFPIA Piperska workshop 19 March 2011 EFPIA members are committed to demonstrating the
More informationDeveloping Drugs for Rare Diseases: Patient Advocacy s Perspective. Kristina Bowyer Executive Director, Patient Advocacy
Developing Drugs for Rare Diseases: Patient Advocacy s Perspective Kristina Bowyer Executive Director, Patient Advocacy February 5, 2018 An Advocacy Perspective Why develop drugs for Rare Disease? What
More informationInnovative Medicines Initiative Sadallah Fatiha IMI JU Office, Brussels, Belgium
Innovative Medicines Initiative 2 2009-2014 Sadallah Fatiha IMI JU Office, Brussels, Belgium The Evolution of IMI: From bottlenecks in industry to bottlenecks in Industry and Society Make Drug R&D processes
More informationFirst Plenary Session CONVERGING OR DIVERGING MODELS OF HTA IN EUROPE. Jean-Luc Harousseau, MD
First Plenary Session Speaker CONVERGING OR DIVERGING MODELS OF HTA IN EUROPE Jean-Luc Harousseau, MD President and Chairman of the Board Haute Autorité de Santé (HAS) Saint-Denis La Plaine, France HTA
More informationThe Innovative Medicines Initiative: Building new models of collaborative research across Europe
The Innovative Medicines Initiative: Building new models of collaborative research across Europe Elisabetta Vaudano IMI, Belgium www.imi.europa.eu What is IMI? An European Public-Private Partnership Focused
More information